Infinity Pharmaceuticals Inc. (INFI) was one of the Russell 2000's biggest losers for Monday January 04 as the stock slid 13.76% to $6.77, a loss of $-1.08 per share. Starting at an opening price of $7.70 a share, the stock traded between $6.55 and $8.16 over the course of the trading day. Volume was 1.52 million shares over 10,431 trades, against an average daily volume of 927,718 shares and a total float of 49.23 million.
The losses send Infinity Pharmaceuticals Inc. down to a market cap of $333.29 million. In the last year, Infinity Pharmaceuticals Inc. has traded between $16.98 and $7.19, and its 50-day SMA is currently $8.64 and 200-day SMA is $10.42.
Infinity Pharmaceuticals Inc is a biopharmaceutical company engaged in discovering, developing & delivering medicines to people with difficult-to-treat diseases. Its primary product candidate is duvelisib, also known as IPI-145, an oral inhibitor.
Infinity Pharmaceuticals Inc. is based out of Cambridge, MA and has some 195 employees. Its CEO is Adelene Q. Perkins.
For a complete fundamental analysis analysis of Infinity Pharmaceuticals Inc., check out Equities.com’s Stock Valuation Analysis report for INFI. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.
The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.
For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.
All data provided by QuoteMedia and was accurate as of 4:30PM ET.